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Abstract In order to identify physiological activators of 
proteinase-activated receptor-2 (PAR-2), a peptide chloro-
methane inhibitor (biotinyl-Ser-Lys-Gly-Arg-CH2Cl) based on 
the cleavage site for activation of PAR-2 was synthesised and 
tested with 12 trypsin-like serine proteinases. The second-order 
rate constant (kJKi) for the formation of the covalent proteinase-
inhibitor complex varied by 2 X 105-fold between the proteinases. 
Biotinyl-Ser-Lys-Gly-Arg-CH2Cl reacted very rapidly with 
trypsin, acrosin from sperm and tryptase from mast cells: the 
k-JKi values with these proteinases were greater than 105 M _ 1 . 
s _ 1 . Thus, the specificity of these proteinases matched the 
sequence of the activation site of PAR-2 and it can be concluded 
that these proteinases are potential physiological activators of 
PAR-2. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
Proteinase-activated receptor-2 (PAR-2) [1] is a member of 
a growing family of G protein-coupled receptors activated by 
proteolytic cleavage of their extracellular amino-terminal do-
main [1-3]. Trypsin can cleave the extracellular domain of 
PAR-2 to generate a tethered ligand analogous to the throm-
bin receptor [1]. However, the widespread distribution of 
PAR-2 in tissues not normally exposed to pancreatic trypsin 
indicates that other physiological activators must exist [4—7]. 
The activator must be a trypsin-like enzyme capable of 
cleaving at the Arg36-Ser37 bond within the PAR-2 extracel-
lular domain (Ser33-Lys-Gly-Arg-Ser-Leu-Ile-Gly40). Thus, us-
ing the nomenclature of Schechter and Berger [8], the physio-
logical activator of PAR-2 should have corresponding subsites 
(S4-S3-S2-S1) for binding the Ser33-Lys-Gly-Arg36 (P4-P3-P2-
P l ) peptide sequence. 
In the present study, we have developed an affinity label 
based on this sequence for serine proteinases capable of acti-
vating PAR-2. A peptidyl chloromethane inhibitor incorpo-
rating the PAR-2 cleavage recognition sequence (biotinyl-Ser-
Lys-Gly-Arg-CH2C1) was tested with a variety of trypsin-like 
serine proteinases in vitro. The results highlighted three can-
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didate enzymes with favourable kinetic profiles that could 
cleave the receptor in vivo, namely pancreatic trypsin, mast 
cell tryptase and acrosin. 
2. Materials and methods 
2.1. Materials 
Human a-thrombin and bovine factor Xa were prepared as de-
scribed [9,10]. Granzyme A was a gift from Prof. J. Tschopp (Institute 
of Biochemistry, University of Lausanne, Switzerland). Human plas-
min, bovine pancreatic TPCK-treated trypsin, human tissue plasmi-
nogen activator (tPA), human plasma kallikrein and TPCK-treated 
trypsin immobilised on agarose were from Sigma (Poole, UK). Hu-
man activated protein C and boar acrosin were produced as described 
[11,12]. Mast cell tryptase purified from human lung was purchased 
from Bioass (Diessen, Germany). The activated complement enzyme 
Cls (Cls) was purchased from Enzyme Research Laboratories (Swan-
sea, UK). The proenzyme Clr was obtained from Calbiochem (Not-
tingham, UK) and activated with immobilised trypsin [13]. The chro-
mogenic substrates Bz-Ile-Glu-Gly-Arg-p-nitroanilide (S-2222), D-Ile-
Pro-Arg-/)-nitroanilide (S-2288), D-Phe-Pip-Arg-/j-nitroanilide (S-
2238), D-Val-Leu-Arg-/)-nitroanilide (S-2266) and D-Pro-Phe-Arg-/>-ni-
troanilide (S-2302) were from Chromogenix (Quadratech, Surrey, 
UK). Methylsulphonyl-D-CHT-Gly-Arg-p-nitroanilide (Spectrozyme 
tPA) was from American Diagnostica Inc. (Greenwich, CT, USA). 
The peptidyl chloromethane inhibitor biotinyl-Ser-Lys-Gly-Arg-
CH2C1 was synthesised as described [14]. Porcine mucosal heparin 
was from Grampian Enzymes (Aberdeen, UK). Bovine serum albu-
min (fraction V) was from Boehringer Mannheim (Mannheim, Ger-
many). Other chemicals were of the highest grade available commer-
cially. 
2.2. Kinetic parameters for the inactivation of proteinases by 
biotinyl-Ser-Lys- Gly-Arg- CH% Cl 
All proteinase assays were performed at 37°C in 0.05 M Tris-HCl 
buffer, pH 7.8, containing 0.1 M NaCl and 0.2% (w/v) poly(ethylene 
glycol) Mr 6000 using a Hewlett-Packard 8452A diode array spectro-
photometer [15]. Assays for activated protein C also included 5 mM 
CaCl2 and 0.1% (w/v) bovine serum albumin and tryptase assays 
contained 10 ug/ml heparin. Estimates for the inactivation rate con-
stant for biotinyl-Ser-Lys-Gly-Arg-CH2Cl were determined by using 
progress curve kinetics [16]. Each progress curve experiment consisted 
of 5-7 assays with different concentrations of biotinyl-Ser-Lys-Gly-
Arg-CH2C1 and an appropriate peptidyl-p-nitroanilide substrate (400 
uM) for the proteinase under study. The peptidyl chloromethane in-
hibitor was added immediately before the assay was started, and the 
reaction was initiated by addition of the proteinase at a concentration 
such that the velocity in the absence of the inhibitor (v0) was in the 
range of 0.5-1.0 uM min - 1 . An absorption coefficient of 9920 M _ 1 
cm - 1 at 405 nm for p-nitroaniline was used in the calculation of the 
amount of product formed [17]. The concentrations of peptidyl-/?-ni-
troanilide substrates were determined spectrophotometrically at 342 
nm using an absorption coefficient of 8270 M _ 1 cm - 1 [17]. The Mi-
chaelis-Menten equation was fitted by non-linear regression to the 
initial rates of hydrolysis of peptidyl-^-nitroanilide substrates, over a 
10-fold range of substrate concentrations to yield estimates for the Km 
values (Table 1). 
The inactivation of a serine proteinase (E) by a peptidyl chloro-
methane inhibitor (I) which competes with substrate (S) in the active 
site of the enzyme can be described by the following scheme, where K\ 
is the dissociation constant for the initial non-covalent complex (El*), 
and k\ is the rate constant for the conversion of the initial complex 
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into the covalent complex (El) in which the active-site histidine is 
alkylated. 
E + I^*i El*- +EI 
For this scheme, the progress curve for the production of p-mtro-
aniline (P) due to substrate cleavage will be given by: 
[P] vst + - (l-e-*') (1) 
where vz is the initial velocity at t = 0, vs is the final steady-state 
velocity and k' is the observed first-order rate constant for the for-
mation of the inhibited proteinase. When all E has been inactivated 
[P] will be constant with time (i.e. vs = 0) and Eq. 1 simplifies to: 
[P]=£(l-e-*'<) (2) 
For this two-step mechanism of irreversible inhibition, the rate 
constant k' is related to k\ by the following relationship: 
k! ■■ m | + ^ ( l + [S]/ATm) (3) 
The value of k' will be dependent on [I] and [S]. In all our experi-
ments we observed a linear dependence of k' on [I], implying that 
[I] <KATi(l + [S]/Km). This will occur when a significant concentration 
of the initial complex does not form. In this case, the dependence of k' 
on [I] is given by: 
U ■-
1 + [S]/Km 
(4) 
where k-JK\ is the second-order rate constant for the formation of 
the inactivated complex (El) and is equivalent to the specificity con-
stant (kCBtIKm) for substrate hydrolysis. The relationship given in Eq. 
4 was substituted into Eq. 2 and the resulting expression was fitted by 
non-linear regression to a progress curve consisting of 5-7 curves with 
different concentrations of biotinyl-Ser-Lys-Gly-Arg-CH2Cl to yield 
estimates for k-JK\. 
3. Results and discussion 
In order to identify possible activators of PAR-2, a peptidyl 
chloromethane based on the activation site of PAR-2 was 
synthesised and tested with a number of serine proteinases. 
The activation site of human PAR-2 consists of the following 
sequence: Ser33-Lys-Gly-Arg-Ser-Leu-Ile-Gly40, where cleav-
age at the Arg36-Ser37 bond leads to receptor activation [4]. 
Thus the affinity label biotinyl-Ser-Lys-Gly-Arg-CH2Cl 
should allow the identification of potential activators. After 
binding of the peptide to the active site, the chloromethane 
moiety alkylates the active-site histidine resulting in covalent 
linking of the inhibitor to the proteinase [18]. The biotin was 
incorporated to allow subsequent detection and purification of 
labelled proteinases from tissue extracts [14]. 
The second-order rate constant kJKi for the formation of 
the covalent proteinase-inhibitor complex is equivalent to the 
specificity constant kc&tIKm for substrate reactions and thus 
measures how closely the sequence of the inhibitor matches 
the specificity of a particular proteinase. Since the sequence of 
the peptidyl chloromethane corresponds to that of the PAR-2 
activation site, the kJKi value also measures whether the spe-
cificity of the proteinase is consistent with a potential role as 
an activator of the receptor. 
Biotinyl-Ser-Lys-Gly-Arg-CH2Cl displayed k\IK\ values 
ranging from 3.1 X105 M _ 1 s_1 with acrosin to 1.8 X101 
M _ 1 s_ 1 with granzyme A (Table 1). The inhibitor reacted 
most rapidly with acrosin, tryptase and trypsin (kJKi > 105 
M _ 1 s_1). Factor Xa was the only other proteinase tested 
that exhibited a relatively high kJK\ value with biotinyl-Ser-
Lys-Gly-Arg-CH2C1 (2X10
4 M _ 1 s"1). A number of protein-
ases (thrombin, activated complement factor Clr (Clr), plas-
min, tissue plasminogen activator (tPA) and plasma kallikrein) 
reacted relatively slowly with biotinyl-Ser-Lys-Gly-Arg-CH2Cl 
(kJKi= 102-103 IVT1 s_1). At the bottom end of the reactivity 
scale were activated complement factor Cls (Cls), activated 
protein C and granzyme A which had k-JK^ values less than 50 
M"1 s_1 with biotinyl-Ser-Lys-Gly-Arg-CH2Cl. 
The observed rapid inhibition of pancreatic trypsin with 
biotinyl-Ser-Lys-Gly-Arg-CH2Cl (k-JK^ 1.12x10
s NT1 s"1) 
correlates with the ability of trypsin to activate PAR-2 in 
vivo [1]. PAR-2 is highly expressed in the pancreas and gas-
trointestinal tract, where it may be activated by pancreatic 
trypsin [4,5]. In support of this hypothesis, trypsin activation 
of PAR-2 stimulates the contraction of gastric smooth muscle 
and the secretion of amylase from pancreatic acini [5,19]. 
However, the expression of PAR-2 is not restricted to the 
gastrointestinal tract and, thus, other activators must exist. 
The present study has identified two other potential activators 
that reacted faster with biotinyl-Ser-Lys-Gly-Arg-CH2Cl than 
trypsin, namely mast cell tryptase and acrosin from sperm. 
Tryptase is a tetrameric trypsin-like enzyme present in mast 
cells, which is released in an active state upon mast cell de-
granulation [20]. The active tetrameric form is stabilised by 
heparin and in the absence of heparin, the tryptase subunits 
dissociate to inactive monomers [21]. The observed rapid in-
Table 1 
Second-order rate constant (k-JKi) for the reaction of biotinyl-Ser-Lys-Gly-Arg-CE^Cl with different serine proteinases 
h/Ki (M"1 s"1) Substrate Km (uM) 
Acrosin 
Tryptase 
Trypsin 
Factor Xa 
Thrombin 
Activated Clr (Clr) 
Plasmin 
Tissue plasminogen activator 
Plasma kallikrein 
Activated Cls (Cls) 
Activated protein C 
Granzyme A 
3.09 ± 0.01 X105 
1.48 ± 0.02 X105 
1.11 ±0.01 XlO5 
2.00 ± 0.02 X104 
1.84 ±0.02 XlO3 
6.33±0.18X102 
6.08 ±0.12 XlO2 
4.34 ±0.01 XlO2 
3.99 ±0.04 XlO2 
4.22 ±0.08 X101 
2.15±0.01xl01 
1.77 ±0.04 X101 
S-2288 
S-2288 
S-2288 
S-2222 
S-2238 
S-2288 
S-2288 
Spectrozyme tPA 
S-2302 
S-2288 
S-2266 
S-2302 
12 
188 
28 
47 
4 
114 
1110 
345 
272 
1800 
222 
1100 
Assays were performed and data analysed as described in Section 2. The estimates of kJK\ obtained are given with the standard errors derived by 
non-linear regression analysis. The substrates used in the assays and their Km values are also shown. 
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activation of tryptase by biotinyl-Ser-Lys-Gly-Arg-CH2Cl (kj 
.Kj = 1 .5Xl0 5 M _ 1 s_ 1) is consistent with previous studies of 
its specificity using synthetic substrates: Lys-Gly-Arg-/>-nitro-
anilide was among the best of the substrates tested [22]. The 
rapid inhibition of mast cell tryptase by biotinyl-Ser-Lys-Gly-
Arg-CH2C1 in vitro is in agreement with the observation that 
tryptase is another physiological activator of PAR-2 in vivo 
[23]. Tryptase is able to cause an increase in cytosolic C a 2 + 
when added to human umbilical vein endothelial cells or ker-
atinocytes which both express PAR-2 [23], eliciting a similar 
response when PAR-2 is activated by either trypsin or an 
agonist peptide in these two cell types [6,7]. 
Acrosin is a trypsin-like serine proteinase that is found in 
large quantities within the acrosomal vesicle of mammalian 
spermatozoa [24]. Like trypsin, acrosin cleaves after arginine 
or lysine residues and has a preference for arginine over lysine 
in the PI position [25]. Acrosin was also rapidly inactivated 
by biotinyl-Ser-Lys-Gly-Arg-CH2Cl with a k-JK^ value of 
3 .1X10 5 M _ 1 s _ 1 (Table 1). Acrosin was inactivated faster 
than trypsin or mast cell tryptase, which have bo th demon-
strated to be physiological activators of PAR-2. This result 
implies that under appropriate conditions acrosin is a poten-
tial activator of PAR-2. In this respect, it is interesting to note 
that Nor thern blot analysis demonstrated PAR-2 expression 
in both the male and female reproductive tract : PAR-2 was 
expressed in prostate and ovary but not in the testis [4,5]. 
In conclusion, the results of the present study have identi-
fied acrosin, tryptase and trypsin as potential physiological 
activators of PAR-2. Biotinyl-Ser-Lys-Gly-Arg-CH2Cl reacted 
very rapidly with trypsin, tryptase and acrosin compared with 
the other proteinases tested. The high degree of selectivity 
exhibited by biotinyl-Ser-Lys-Gly-Arg-CH2Cl for both acro-
sin and tryptase provides a useful affinity label for the study 
of these two trypsin-like serine proteinases. It should also be 
possible to use the biotinylated affinity label in future studies 
in conjunction with SDS-PAGE and Western blotting tech-
niques, for the detection and partial characterisation of other 
potential activators of PAR-2. 
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